Join the Hepatocellular Carcinoma group to help and get support from people like you.
Hepatocellular Carcinoma News
Related terms: Malignant Hepatoma, HCC, Liver Cancer
Adding Vaccine to Immunotherapy for Liver Cancer Shows Promise in Early Trial
TUESDAY, April 9, 2024 – A custom-made anti-tumor vaccine added to standard immunotherapy was twice as likely to shrink liver cancer as when a patient received immunotherapy alone, a new study...
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
MONDAY, Jan. 29, 2024 – For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization...
Mexican Americans Face Higher Odds for Liver Cancer With Each New Generation
WEDNESDAY, Nov. 22, 2023 – The risk of developing liver cancer appears to be rising with each successive generation of Mexican-Americans, especially men, a new report finds. “Liver cancer is b...
Direct-Acting Antivirals Still Underused in Hep C-Related Liver Cancer
TUESDAY, Nov. 21, 2023 – Direct-acting antiviral agents (DAAs) remain underutilized in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), according to a study presented at...
Increasing Generational Status Linked to Elevated Risk for Liver Cancer
MONDAY, Nov. 20, 2023 – For Mexican Americans, increasing generational status is associated with an increased risk for hepatocellular carcinoma (HCC), according to a study published online Nov. 20...
Hepatitis C Virus Still Leading Cause of Hepatocellular Cancer in Men
THURSDAY, Sept. 7, 2023 – The leading cause of hepatocellular carcinoma (HCC) is still hepatitis C virus (HCV) among men, but the rates of HCV-HCC have decreased since 2015, according to a study...
Mortality Rates High for People Successfully Treated for Hep C
WEDNESDAY, Aug. 9, 2023 – Mortality rates are high for people successfully treated for hepatitis C virus (HCV) in the era of interferon-free direct-acting antivirals, according to a study published...
Sugary Drinks Raise Women's Odds for Liver Disease, Cancer
WEDNESDAY, Aug. 9, 2023 – There are plenty of reasons to steer clear of sugary drinks, and new research highlights yet another one: Women who drink sodas and other sweetened drinks have a higher...
Sugar-Sweetened Drinks Linked to Increased Incidence of Liver Cancer, Mortality
TUESDAY, Aug. 8, 2023 – Intake of sugar-sweetened beverages is associated with an increased incidence of liver cancer and death from chronic liver disease among postmenopausal women, according to a...
Combo Therapy May Prevent Cancer's Return After Liver Surgery
MONDAY, April 24, 2023 – A two-drug combination therapy can enhance survival odds for people with early-stage liver cancer through targeted attacks on tumor cells, a new clinical trial shows. The...
FDA Approves Imjudo (tremelimumab) in Combination with Imfinzi for Patients with Unresectable Hepatocellular Carcinoma
24 October 2022 – AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular c...
FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
South San Francisco, CA – May 29, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...
Lilly's Cyramza (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
INDIANAPOLIS, May 13, 2019 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL...
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 14, 2019-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for patients...
FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
KENILWORTH, N.J.--(BUSINESS WIRE) November 9, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Ask a question
To post your own question to this support group, sign in or create an account.